Human Immunology News Volume 3.45 | Nov 17 2015

IL-36α: A Novel Cytokine Involved in the Catabolic and Inflammatory Response in Chondrocytes
OA chondrocytes expressed more IL-36α than healthy chondrocytes. Immune cells infiltrated into the joint and PBMCs expressed higher levels of IL-36α in comparison to chondrocytes. [Sci Rep] Full Article

Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration
The authors previously showed that, when peripheral blood mononuclear cells (PBMCs) were stressed with ionizing radiation, they released paracrine factors that showed regenerative capacity in vitro and in vivo. In this study, they aimed to characterize the secretome of PBMCs and to investigate its biologically active components in vitro and in vivo. [Sci Rep] Full Article

CD40 Ligand-Expressing Recombinant Vaccinia Virus (rVV40L) Promotes the Generation of CD8⁺ Central Memory T Cells
Scientists generated a replication incompetent CD40 ligand-expressing recombinant vaccinia virus to promote the differentiation of human naïve CD8⁺ T cells into central memory CD8⁺ T cells specific for viral and tumor associated antigens. [Eur J Immunol] Abstract

Combination of Cytokine-Induced Killer and Dendritic Cells Pulsed with Antigenic α-1,3-Galactosyl Epitope–Enhanced Lymphoma Cell Membrane for Effective B-Cell Lymphoma Immunotherapy
Incubation of processed cell membranes with autologous dendritic cells (DCs) in the presence of human serum containing abundant natural anti–α-1,3-galactosyl immunoglobulin G led to the effective phagocytosis of tumor membranes by DCs. [Cytotherapy] Abstract

miR-27a and miR-214 Exert Opposite Regulatory Roles in Th17 Differentiation via Mediating Different Signaling Pathways in Peripheral Blood CD4⁺ T Lymphocytes of Patients with Relapsing–Remitting Multiple Sclerosis
Researchers assessed transcript levels of miR-27a and miR-214, in purified CD4⁺ T cells of multiple sclerosis patients, during relapsing and remitting phases in inducing differentiation of T naïve cells to T helper 17 (Th17) cells. [Immunogenetics] Abstract

Profiling of Primary Peripheral Blood- and Monocyte-Derived Dendritic Cells Using Monoclonal Antibodies from the HLDA10 Workshop in Wollongong, Australia
Scientists compared the reactivity patterns of HLDA10 antibodies with plasmacytoid dendritic cells (DCs), CD1c⁺ DCs and CD141⁺ DCs, as well as with CD14⁺-derived monocyte-derived DCs cultured for seven days in the presence of granulocyte–macrophage colony-stimulating factor plus interleukin-4. [Clin Transl Immunol] Full Article

Myeloid Cells as Target of Fingolimod Action in Multiple Sclerosis
In vitro and ex vivo immunologic studies coupled with flow cytometry were performed to evaluate the action of fingolimod on lipopolysaccharide–induced expression of activation markers in human monocytes from healthy participants, participants with untreated multiple sclerosis (MS), and participants with fingolimod-treated MS. [Neuroimmunol Neuroinflamm] Full Article | Editorial

Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

Visit our reviews page to see a complete list of reviews in the Human Immunology research field.

Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies
Kineta, Inc. presented new, positive dalazatide data from its recent Phase Ib active plaque psoriasis clinical trial as well as encouraging dalazatide research in lupus from its collaboration with Seattle Children’s Research Institute and in ANCA Vasculitis from its study with the University of Groningen. [Press release from Kineta, Inc. discussing research presented at the 2015 ACR/ARHP Annual Meeting, San Francisco] Press Release

From our sponsor: Working with blood? Download the immune cell frequencies app.

Bavarian Nordic Announces Results of a Phase I Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced Cancer
Bavarian Nordic A/S announced results from an NCI-sponsored Phase I study investigating its novel cancer vaccine, MVA-BN^® Brachyury. Data from this study demonstrate for the first time that an MVA-BN based vaccine targeting brachyury can induce brachyury-specific T-cell immune responses in advanced cancer patients. [Bavarian Nordic A/S] Press Release

Celltrion Submits Second Biosimilar for Approval to European Regulator
Celltrion announced that it filed a request for European Medicines Agency approval of CT-P10. CT-P10 is a candidate biosimilar of rituximab, which is used to treat hematological cancer, rheumatoid arthritis and transplant rejection. [Celltrion Inc. (BusinessKorea Co., Ltd.)] Press Release

CEL-SCI IS Granted a New European Patent on Its Phase III Investigational Cancer Immunotherapy Multikine
CEL-SCI Corporation announced that it has been granted a European patent on Multikine, its investigational Phase III cancer immunotherapy. [CEL-SCI Corporation] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the Human Immunology community.

NEW Postdoctoral Fellow – Immunology (Medical College of Wisconsin)

NEW Postdoctoral Fellow – Transplantation Immunology (H. Lee Moffitt Cancer Center & Research Institute)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Assistant Professor – Cancer Immunology (Children’s Hospital of Philadelphia)

Postdoctoral Position – Immunology and Cell Biology (Beth Israel Deaconess Medical Center)

Staff Scientist – Immunology (Benaroya Research Institute at Virginia Mason)

Postdoctoral Research Fellow – Molecular Oncology (Genentech, Inc.)

Professor – Immunology (La Jolla Institute for Allergy & Immunology)

Principal Investigator – The Role of Inflammation and the Immune Response in Regenerative Medicine (KU Leuven)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.